Eliquis Poised To Wake Up U.S. Oral Anticoagulant Market
Bad press and lawsuits related to bleeding events for Boehringer Ingelheim’s novel anticoagulant Pradaxa create a window of opportunity for Eliquis, which is pending approval in the U.S. and could have what it takes to tip the market away from generic warfarin.
You may also be interested in...
US payers may increasingly look to leverage the competition among the novel oral anticoagulants by contracting for preferred coverage with two of the leading drugs in the field, rather than all three.
A report suggests that Aptalis Pharma is on the block, but is the price too high? Also, Quintiles spends some of its IPO war chest on a smaller North Carolina CRO, and Pfizer strikes a diabetes deal with Sanford-Burnham.
Pharmaceutical sales forces have taken a huge hit over the last few years as the industry reorganizes and shifts its priorities. Yet, experts believe that pharma companies will begin hiring reps back in coming years as they believe more new drugs will be approved.